上尿路尿路上皮癌Slit引导配体3的表达与临床病理特征以及预后的关系

目的 观察Slit引导配体3（Slit guidance ligand 3，Slit3）在上尿路尿路上皮癌（upper tract urothelial carcinoma，UTUC）中的表达及其与UTUC临床病理特征以及预后的关系。方法 采用免疫组织化学方法检测Slit3在UTUC中的表达，并运用相关统计学方法分析Slit3表达与UTUC临床病理特征（包括患者年龄、性别、组织学分级、分期和大片坏死等）以及预后的关系。结果 在UTUC患者中，Slit3表达随着肿瘤组织学分级和分期的增高而减低（P=0.014和P=0.006），Slit3还与肿瘤膀胱复发具有相关性（P=0.011）。在单因素生存分析中，Slit3低表达与UTUC患者的较短无病生存期和癌特异性生存期均相关（P=0.006，P=0.015），但在多因素生存分析中无统计学意义（P=0.213，P=0.332）。结论 Slit3的低表达与肿瘤高分级、高分期以及膀胱复发相关，但不影响UTUC的预后。

Expression and significance of Slit guidance ligand 3 in upper tract urothelial carcinoma

Objective To observe the expression of Slit guidance ligand 3(Slit3) in upper tract urothelial carcinoma (UTUC) and its relationship with the clinicopathological features and prognosis of UTUC patients. Methods The expression of Slit3 in UTUC was detected by immunohistochemical method, and the association of Slit3 expression with the clinicopathological features of UTUC (including age, sex, histological grade, stage and extensive necrosis, etc.) and prognosis were analyzed. Results For UTUC patients, the Slit3 expression decreased with the increased histological grade and tumor stage (P=0.014, P=0.006). Slit3 was also associated with the bladder recurrence (P=0.011). In univariate survival analysis, the lower Slit3 expression was associated with the shorter disease-free survival and cancer-specific survival in UTUC patients (P=0.006, P=0.015), but it was not statistically significant in multivariate analysis (P=0.213, P=0.332). Conclusion Slit3 is likely to be involved in the progression of UTUC. The lower expression of Slit3 is associated with the higher tumor grade, stage and bladder recurrence rate, however, Slit3 is not an independent prognostic factor for UTUC patients.